These findings provide further insight into the efflux transporter interactions of asciminib and updated evidence on nilotinib and bosutinib transport by P-gp, with implications for drug resistance and treatment optimization in CML. The gene discussed is PGP; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.